Logo image of NKTR

NEKTAR THERAPEUTICS (NKTR) Stock Fundamental Analysis

NASDAQ:NKTR - Nasdaq - US6402681083 - Common Stock - Currency: USD

22.775  -0.5 (-2.13%)

Fundamental Rating

3

NKTR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. NKTR has a great financial health rating, but its profitability evaluates not so good. NKTR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NKTR has reported negative net income.
In the past year NKTR has reported a negative cash flow from operations.
In the past 5 years NKTR always reported negative net income.
In the past 5 years NKTR always reported negative operating cash flow.
NKTR Yearly Net Income VS EBIT VS OCF VS FCFNKTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

NKTR's Return On Assets of -51.92% is on the low side compared to the rest of the industry. NKTR is outperformed by 61.14% of its industry peers.
The Return On Equity of NKTR (-968.42%) is worse than 81.35% of its industry peers.
Industry RankSector Rank
ROA -51.92%
ROE -968.42%
ROIC N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
NKTR Yearly ROA, ROE, ROICNKTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

The Gross Margin of NKTR (74.61%) is better than 83.94% of its industry peers.
In the last couple of years the Gross Margin of NKTR has declined.
NKTR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
NKTR Yearly Profit, Operating, Gross MarginsNKTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

7

2. Health

2.1 Basic Checks

NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NKTR has been reduced compared to 1 year ago.
NKTR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NKTR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NKTR Yearly Shares OutstandingNKTR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NKTR Yearly Total Debt VS Total AssetsNKTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

NKTR has an Altman-Z score of -19.68. This is a bad value and indicates that NKTR is not financially healthy and even has some risk of bankruptcy.
NKTR has a Altman-Z score of -19.68. This is in the lower half of the industry: NKTR underperforms 79.79% of its industry peers.
There is no outstanding debt for NKTR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.68
ROIC/WACCN/A
WACC9.33%
NKTR Yearly LT Debt VS Equity VS FCFNKTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

NKTR has a Current Ratio of 3.24. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
NKTR has a Current ratio of 3.24. This is comparable to the rest of the industry: NKTR outperforms 56.99% of its industry peers.
NKTR has a Quick Ratio of 3.24. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NKTR (3.24) is better than 60.62% of its industry peers.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 3.24
NKTR Yearly Current Assets VS Current LiabilitesNKTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.78% over the past year.
The Revenue has decreased by -3.19% in the past year.
NKTR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.00% yearly.
EPS 1Y (TTM)9.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.32%
Revenue 1Y (TTM)-3.19%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-51.73%

3.2 Future

The Earnings Per Share is expected to grow by 14.42% on average over the next years. This is quite good.
NKTR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.59% yearly.
EPS Next Y-2.04%
EPS Next 2Y-29.84%
EPS Next 3Y-6.47%
EPS Next 5Y14.42%
Revenue Next Year-56.51%
Revenue Next 2Y-36.52%
Revenue Next 3Y-29.84%
Revenue Next 5Y-1.59%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NKTR Yearly Revenue VS EstimatesNKTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
NKTR Yearly EPS VS EstimatesNKTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 20 -20 40 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKTR. In the last year negative earnings were reported.
Also next year NKTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTR Price Earnings VS Forward Price EarningsNKTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTR Per share dataNKTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

NKTR's earnings are expected to decrease with -6.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.84%
EPS Next 3Y-6.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NKTR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEKTAR THERAPEUTICS

NASDAQ:NKTR (8/5/2025, 1:28:47 PM)

22.775

-0.5 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners66.83%
Inst Owner Change-1.03%
Ins Owners1.29%
Ins Owner Change-2.19%
Market Cap379.43M
Analysts81.43
Price Target96.73 (324.72%)
Short Float %7.06%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.23%
Min EPS beat(2)-43.22%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-10.13%
Min EPS beat(4)-43.22%
Max EPS beat(4)16.31%
EPS beat(8)4
Avg EPS beat(8)-6.42%
EPS beat(12)7
Avg EPS beat(12)-0.13%
EPS beat(16)11
Avg EPS beat(16)3.33%
Revenue beat(2)0
Avg Revenue beat(2)-18.76%
Min Revenue beat(2)-33.31%
Max Revenue beat(2)-4.21%
Revenue beat(4)2
Avg Revenue beat(4)5.78%
Min Revenue beat(4)-33.31%
Max Revenue beat(4)31.25%
Revenue beat(8)5
Avg Revenue beat(8)11.78%
Revenue beat(12)7
Avg Revenue beat(12)7.85%
Revenue beat(16)8
Avg Revenue beat(16)5.31%
PT rev (1m)28.59%
PT rev (3m)1828.8%
EPS NQ rev (1m)-3.76%
EPS NQ rev (3m)-1763.56%
EPS NY rev (1m)5.59%
EPS NY rev (3m)-1672.81%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-40.77%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)-40.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.35
P/FCF N/A
P/OCF N/A
P/B 27.62
P/tB 27.62
EV/EBITDA N/A
EPS(TTM)-12.45
EYN/A
EPS(NY)-19.72
Fwd EYN/A
FCF(TTM)-10.7
FCFYN/A
OCF(TTM)-10.62
OCFYN/A
SpS5.24
BVpS0.82
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.92%
ROE -968.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.61%
FCFM N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
F-Score3
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.9%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 3.24
Altman-Z -19.68
F-Score3
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)29.45%
Cap/Depr(5y)49.23%
Cap/Sales(3y)2.88%
Cap/Sales(5y)5.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.32%
EPS Next Y-2.04%
EPS Next 2Y-29.84%
EPS Next 3Y-6.47%
EPS Next 5Y14.42%
Revenue 1Y (TTM)-3.19%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-51.73%
Revenue Next Year-56.51%
Revenue Next 2Y-36.52%
Revenue Next 3Y-29.84%
Revenue Next 5Y-1.59%
EBIT growth 1Y-5.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.64%
EBIT Next 3Y-8.45%
EBIT Next 5YN/A
FCF growth 1Y33.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.88%
OCF growth 3YN/A
OCF growth 5YN/A